- Cara Therapeutics is developing its CR701 as an alternative to opioids
STAMFORD, Conn. (AP) _ Cara Therapeutics Inc. (CARA) on Thursday reported a loss of $9.3 million in its second quarter.
The Stamford, Connecticut-based company said it had a loss of 29 cents per share.
The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 62 cents per share.
Cara shares have increased 43 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $13.30, more than doubling in the last 12 months.
No comments:
Post a Comment